Skip to main content

Table 1 Characteristics of study subjects (n = 93) stratified by N-BP exposure and the occurrence of bisphosphonate-associated osteonecrosis of the jaw (ONJ)

From: Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw

Group N Mean age (years ± SD) Median length of time on N-BP therapy (days, range) Characteristics and type of N-BP therapy
N-BP treatment naïve controls 26 66.4 ± 10.0 NA 18 with osteoporosis (mean age 72.1 ± 6)
8 Postmenopausal women without osteoporosis (mean age 53.6 ± 2)
Oral N-BP 30 74.1 ± 5.7 90 (1,764) 90% On oral alendronate (70 mg/week); 10% on oral ibandronate (150 mg/months)
Intravenous N-BP 31 73.2 ± 5.5 813 (1,982) All on intravenous ibandronate (3 mg/months)
ONJ 6 61.3 ± 12.5 1,113 (1,282) 1 Woman (85 yrs) was being treated with 5 mg/year intravenous zoledronate (had received 2 shots) for osteoporosis, previously had a blood malignancy and was on prednisone
1 Woman on systemic corticosteroids and mycophenolate mofetil on oral aledronate (70 mg/week) for 3.5 years
1 Woman on interferon therapy for hepatitis B & C on oral aledronate (70 mg/week) for 5 years
3 Women who had been treated for metastatic breast cancer; all on 4 mg/months intravenous zoledronate (from 1.4 to 2.8 years)